Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025Blood

TCR-T cells targeting a public neoantigen produced by the SF3B1 K700E mutation kill SF3B1-mutant AML/MDS

View Full Paper
Ask AI
Bookmark
Share

Authors

NTNoah TuboYHYanqing HuangXMXizeng Mao

Discussion

Loading...

Member takes

Overview

T cell-based therapies targeting the SF3B1 K700E neoantigen kill AML/MDS leukemia cells, highlighting potential as a treatment.

Key Points

  • TCR-T cells effective against leukemia cells expressing SF3B1 K700E, leading to improved survival based on in vivo model findings.
  • Peptide dose-response experiments identified highly potent TCR with a preference for mutant over wild type SF3B1 sequences.
  • Cytotoxicity assays confirmed the TCR-T cells discriminate and kill myeloid neoplasm cells, without damaging healthy tissues.
  • Findings suggest potential applicability of T cell-based therapies targeting neoantigens in treating leukemic stem cells.

Cite This Study

Tubo et al. (2025) studied this question.

synapsesocial.com/papers/69362f604fa91c937236dd9chttps://doi.org/10.1182/blood-2025-2363
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Simultaneous high-throughput identification of myeloid leukemia driver mutation-derived public neoantigens and cognate functional TCRs for TCR-T therapy2025
  2. 2Acute Myeloid Leukemia eradication targeting cathepsin g with a dual HLA-restricted TCR2025
  3. 3A case of co-mutation of SF3B1 and BCR::ABL1 demonstrating an MDS-phenotype2025 · 1 citations
  4. 4SF3B1 mutations K700E, K666N, and R625H: Gene expression and aberrant splicing consequences2025
  5. 5Impact of different Sf3b1 mutations on hematopoietic function and erythropoiesis2025